News | August 09, 2022
Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
Subscribe To Our Newsletter & Stay Updated
